Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations Transcript

Core Points - The call is hosted by Protara, focusing on updates relevant to investors and corporate affairs [1] Group 1 - The conference is being recorded, and participants are reminded to hold questions until the formal remarks are completed [1] - Justine O'Malley, Senior Vice President, is leading the call and will provide insights into the company's current status [1]